Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

D2446

Daptomycin

cyclic lipopeptide antibiotic

Sinónimos:

Cubicin, Daptomycin, 9-L beta-Aspartic Acid, Dapcin

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C72H101N17O26
Número CAS:
103060-53-3
Peso molecular:
1620.67
MDL number:
MFCD28968054
UNSPSC Code:
51102829
PubChem Substance ID:
329798741
NACRES:
NA.76
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Quality Level

100

assay

≥90% (HPLC)

form

powder

solubility

methanol: 5 mg/mL, DMSO: soluble, ethanol: soluble, methanol: soluble

antibiotic activity spectrum

Gram-positive bacteria

mode of action

DNA synthesis | interferes, protein synthesis | interferes

storage temp.

−20°C

SMILES string

CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)c4ccccc4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O

InChI

1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43-,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1

InChI key

DOAKLVKFURWEDJ-FAZHXZQASA-N

Application

Daptomycin has been studied as a potential therapy for Streptococcus pneumoniae infections. It has also been used to study the impact of sarA on daptomycin susceptibility of Staphylococcus aureus.

Biochem/physiol Actions

Daptomycin is a cyclic lipopeptide antibiotic. isolated from Streptomyces sp. It is effective against Gram-positive bacteria. It disrupts the plasma membrane causes rapid depolarization and inhibits the synthesis of protein, RNA and DNA. It is potent against Staphylococcus aureus infections, including MRSA (methicillin-resistant Staphylococcus aureus).

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Still not finding the right product?

Explore all of our products under

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000417606
0000417606
0000395351
0000311947
0000395351

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Romney M Humphries et al.
Clinical microbiology reviews, 26(4), 759-780 (2013-10-05)
Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-positive bacteria that was first approved for clinical use in 2004 in the United States. Since this time, significant data have emerged regarding the use of daptomycin for the
Nigam M Mishra et al.
Frontiers in microbiology, 9, 1175-1175 (2018-06-23)
Vancomycin is a glycopeptide antibiotic that inhibits transpeptidation during cell wall synthesis by binding to the D-Ala-D-Ala termini of lipid II. For long, it has been used as a last resort antibiotic. However, since the emergence of the first vancomycin-resistant
Elizabeth C Weiss et al.
Antimicrobial agents and chemotherapy, 53(10), 4096-4102 (2009-08-05)
We used a murine model of catheter-associated biofilm formation to determine whether the mutation of the staphylococcal accessory regulator (sarA) has an impact on the susceptibility of established Staphylococcus aureus biofilms to treatment with daptomycin in vivo. The experiments were
Ver todos los artículos relacionados